MXCT vs SPGI · rev $38.6M vs P/E 27, rev $15.34B
MaxCyte Inc (MXCT) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
MaxCyte Inc (MXCT) is a medical devices company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported MXCT revenue for 2024-12-31 was $38.6M. Net income was -$41.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. MXCT currently screens at market cap $124.3M.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
MXCT currently screens at market cap $124.3M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the MXCT and SPGI stock pages for the full models.
Not investment advice.